DOCSLIB.ORG

Abstracts from 26Th Nordic-Baltic Congress of Cardiology in Vilnius, Lithuania, June 1-3, 2017 Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstracts from 26Th Nordic-Baltic Congress of Cardiology in Vilnius, Lithuania, June 1-3, 2017 Contents Abstracts from 26th NORDIC-BALTIC CONGRESS OF CARDIOLOGY in Vilnius, Lithuania, June 1-3, 2017 CONTENTS 1. A DYING PATIENT IN INTENSIVE CARE UNIT – AN ETHICAL APPROACH. Vitas Vyšniauskas, Daiva Petraskiene ................................................................................................................................................................ 7 2. SECONDARY PREVENTION OF STABLE CORONARY HEART DISEASE ON THE BACKGROUND OF NON-ALCOHOLIC STEATOHEPATITIS. Iryna Vakalyuk, Virstyuk Nataliya ......................................................... 8 3. ORAL ANTICOAGULANTS AFTER PULMONARY EMBOLISM: REAL – LIFE OUTCOMES AND DURATION OF TREATMENT. Valdis Ģībietis, Dana Kigitoviča, Barbara Vītola, Sintija Strautmane, Andris Skride ...................................................................................................................................................................... 9 4. ASSOCIATION OF CLOT LOCATION WITH DIAGNOSTIC MARKERS AND OUTCOMES OF ACUTE PULMONARY EMBOLISM. Valdis Ģībietis, Dana Kigitoviča, Barbara Vītola, Sintija Strautmane, Andris Skride ..................................................................................................................................... 10 5. THE EFFICIENCY OF TREATMENT BY BISOPROLOL IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY. Feiskhanova L.I., Kharisova N., Boichuk Y., Nigmatyanova A.A., Haliullina L.R. .................. 11 6. STATISTIC REVIEW OF PATIENTS WITH CARDIOLOGIC EVENTS WHO ARE USING ANTICOAGULANTS – TOTAL AMOUNT OF DAILY USED DRUGS AND WITHIN THE NUMBER OF DRUGS THAT CAN INTERACT WITH ANTICOAGULANTS. Estere Urbančika, Linda Kalniņa, Prof. Oskars Kalējs ........................................................................................................................................................... 12 7. CHANGES OF LEFT VENTRICLE SYSTOLIC FUNCTION AND MECHANICS IN PRECAPILLARY PULMONARY HYPERTENSION: CMR FEATURE TRACKING STUDY. Padervinskiene Lina, Miliauskas Skaidrius, Hoppenot Deimante, Jankauskas Antanas, Krivickiene Ausra, Gumauskiene Birute, Galnaitiene Gryte, Simkus Pauliusa, Ereminiene Egle ..................................................................................................... 13 8. LONGITUDINAL AND CIRCUMFERENTIAL DEFORMATION PARAMETERS DURING RECOVERY PHASE AFTER DOBUTAMINE SPECKLE TRACKING ECHOCARDIOGRAPHY IN ASSESING MYOCARDIAL ISCHEMIA FOR PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE. E. Rumbinaite, A. Karuzas, I. Jonauskiene, M. Kinderytė, M.Viezelis, R. Slapikas, J.J. Vaškelytė .............................. 14 9. PRESSURE AND VOLUME OVERLOAD DIFFERENTLY AFFECT THE RELATIVE CONTRIBUTION OF LONGITUDINAL AND RADIAL COMPONENTS OF RIGHT VENTRICULAR WALL DISPLACEMENT TO GLOBAL RIGHT VENTRICULAR EJECTION FRACTION. Bidviene J, Kovacs A, Lakatos B, Surkova E, Muraru D, Famoso G, Ereminiene E, Vaskelyte JJ, Iliceto S, Badano LP ..................................................... 15 10. IN PHYSIOLOGICAL CONDITIONS, THE RADIAL AND LONGITUDINAL COMPONENTS OF RIGHT VENTRICULAR WALL MOTION CONTRIBUTE EQUALLY TO GLOBAL RIGHT VENTRICULAR EJECTION FRACTION. A 3-DIMENSIONAL ECHOCARDIOGRAPHY STUDY Bidviene J, Surkova E, Kovacs A, Lakatos B, Muraru D, Rodriguez-Zanella H, Ereminiene E, Vaskelyte JJ, Iliceto S, Badano LP .................................................................................................................................... 16 11. FACTORS INFLUENCING X-RAY EXPOSURE IN THE ELECTROPHYSIOLOGY LAB. Denis Šileikis, Tomas Kazakevičius, MD, Vytautas Zabiela, MD, Vytautas Šileikis, MD, Vilius Kviesulaitis, MD, Aras Puodžiukynas, MD ........................................................................................................... 17 12. EFFICACY OF PULMONARY VEIN ISOLATION USING A SECOND-GENERATION CRYOBALLOON FOR PATIENTS WITH ATRIAL FIBRILLATION. Germanas Marinskis, Gediminas Rackauskas, Gabrielius Jakutis, Dovile Jancauskaite, Justinas Bacevicius, Diana Sudaviciene, Paulius Jurkuvenas, Kestutis Bagdonas, Jurate Barysiene, Aiste Zebrauskaite, Audrius Aidietis ................................................................................................................................................................ 19 13. RETROSPECTIVE AND PROSPECTIVE ANALYSIS OF ANTITHROMBOTIC STRATEGY A ND COMPLICATIONS RATE AMONG PATIENTS WITH ATRIAL FIBRILLATION AFTER PERCUTANEOUS CORONARY INTERVENTION. Deimilė Balkutė, Taida Ivanauskiene, Gediminas Rackauskas, Dovile Jancauskaite, Giedrius Davidavičius, Germanas Marinskis, Audrius Aidietis .............. 20 14. EXERCISE BASED CARDIAC REHABILITATION AFTER HEART SURGERY. Eglė Tamulevičiūtė-Prascienė, Jurate Petrauskaite, Juste Galminaite, Kristina Drulyte, Raimondas Kubilius ............... 22 15. RISK FACTORS OF RECCURENCE OF STABLE CORONARY HEART DISEASE: OXIDATIVE STRESS AND DEPRESSION. Ivascenko T., Voicehovskis V.V., Kalejs O., Voicehovska.J.G., Skesters A., Apsite K. ........................................................................................................................................................................... 23 16. ENPEP GENE’S VARIATION rs6825911 IS ASSOCIATED WITH RECURRENCE OF ATRIAL FIBRILLATION AFTER SINUS RHYTHM RESTORATION. Irina Rudaka, Dmitrijs Rots, Arturs Uzars, Lubova Grinevica, Oskars Kalejs, Linda Piekuse ............................................................................................................ 25 17. CORRECTION OF RESPIRATORY SYNDROME IN PATIENTS WITH ARTERIAL HYPERTENSION TREATED WITH ANGIOTENSIN – CONVERTING ENZYME INHIBITORS.Sovtus Volodymyra, Virstyuk Nataliya .............................................................................................................................................................. 26 2 18. ENDOTHELIAL FUNCTION ASSESED BY PERIPHERAL ARTERIAL TONOMETRY IS NOT RELATED TO CARDIOVASCULAR RISK SCORE IN HEALTHY SUBJECTS. Ylfa Run Sigurdardottir, Bylgja Run Stefansdottirb, Thor Aspelund, Gudmundur Thorgeirsson, Linda Bjork Kristinsdottir, Vilmundur Gudnason, Karl Andersen ............................................................................................................................... 27 19. THE IMPACT OF GLYCAEMIC PARAMETERS, C PEPTIDE AND HOMA-IR INDEX ON CORONARY PLAQUE TISSUE CHARACTERISTICS ASSESED BY iMAP-INTRAVASCULAR ULTRASOUND IN PATIENTS WITH PREDIABETES. Evija Knoka, Karlis Trusinskis, Inga Narbute, Dace Sondore, Indulis Kumsars, Sanda Jegere, Ieva Briede, Rudolfs Roze, Karlis Strenge, Andrejs Erglis ........................................... 28 20. LOW CARDIOVASCULAR EVENT AND HIGH ATRIAL FIBRILLATION RECURRENCE RATE ON YEAR AFTER ELECTRIC CARDIOVERSION. Irina Pupkevica, Irina Cgojeva-Sproge, Baiba Lurina, Ginta Kamzola, Oskars Kalejs .......................................................................................................................................... 29 21. THE OUTCOMES OF THE INPATIENT TREATMENT OF THE CARDIAC PATIENTS, WHO HAS SURVIVED THE CLINICAL DEATH AND EXPERIENCED THE CORONARY ANGIOGRAPHY. Barauskas M, Unikas R, Ziubryte G ................................................................................................................................ 30 22. LOW DOSE CARDIAC CTA IN OBESE PATIENTS. Golubickas D , Naujokaitė E , Jankauskas A , Slapikas R .. 31 23. STATISTIC REVIEW OF PATIENTS WITH CARDIOLOGICAL EVENTS WHO ARE USING ANTICOAGULANTS – TOTAL AMOUNT OF DAILY USED DRUGS AND WITHIN THOSE THE NUMBER OF DRUGS THAT CAN INTERACT WITH ANTOCOAGULANTS. Estere Urbančika, Linda Kalniņa ..................... 32 24. FEATURES OF THE ELECTROPHYSIOLOGICAL REMODELING OF THE HEART IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HYPERTENSION. Feishkanova L. Kharisova N. Boichuk Y. Nigmatyanova A. .............................................................................................................................................................. 33 25. THE EFFICIENCY OF TREATMENT BY BISOPROLOL IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY. Feishkanova L. Kharisova N. Boichuk Y. Nigmatyanova A. ..................................................... 34 26. IS UNDER-USE OF THE MINERALOCORTICOID RECEPTOR ANTAGONISTS AFTER THE HOSPITALIZATION DUE TO ACUTE HEART FAILURE ASSOCIATED WITH WORSE CLINICAL OUTCOMES? D.Verikas, V. Polevoda, A.Mebazaa, A.Kavoliūnienė, J.Čelutkienė, on behalf of the GREAT network ............................................................................................................................................................................ 35 27. PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND HEART FAILURE: DATA FROM ESTONIAN NATIONAL REGISTRY OF MYOCARDIAL INFARCTION. T. Uuetoa, M. Tammaru, G. Veldre ......... 36 28. RIGHT VENTRICULAR SYSTOLIC AND DIASTOLIC DEFORMATION IN PATIENTS WITH ISCHEMIC MITRAL REGURGITATION AFTER INFEROPOSTERIOR MYOCARDIAL INFARCTION Tamulenaite E, Valuckiene Z, Jurkevicius R ................................................................................................................... 38 29. THE IMPACT OF CLINICAL AND AGIOGRAPHIC FACTORS ON PERCUTANEOUS CORONARY ANGIOPLASTY OUTCOMES IN PATIENTS WITH ACUTE ST-ELEVATION MYOCARDIAL INFARCTION Tamulenaite E, Barauskas M, Unikas R ........................................................................................................................... 39 30. THE RATES OF ASPIRIN AND STATIN THERAPY IN PATIENTS WITH NON-OBSTRUCTIVE CORONARY ARTERY DISEASE, Tamulenaite E, Sasnauskaite J, Ilginis D, Ceponiene I, Golubickas D ................... 40 31. CHARACERIZATION OF LEFT VENTRICULAR MORPHOLOGY
Load more

Recommended publications
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Compositions for Treating Itch Zusammensetzungen Zur Behandlung Von Juckreiz Compositions Pour Traiter Les Démangeaisons
    (19) TZZ Z¥_T (11) EP 2 446 903 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/085 (2006.01) A61K 31/165 (2006.01) 09.10.2019 Bulletin 2019/41 A61K 31/167 (2006.01) A61K 31/14 (2006.01) A61K 9/00 (2006.01) A61K 45/06 (2006.01) (2006.01) (2006.01) (21) Application number: 11007949.8 A61P 17/04 A61P 29/00 (22) Date of filing: 19.11.2007 (54) Compositions for treating itch Zusammensetzungen zur Behandlung von Juckreiz Compositions pour traiter les démangeaisons (84) Designated Contracting States: WO-A2-99/11252 US-A- 3 519 631 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR US-A- 4 069 309 US-B1- 6 362 197 HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE US-B1- 6 413 961 SI SK TR • OMANA-ZAPATA I ET AL: "QX-314 inhibits (30) Priority: 20.11.2006 US 860124 P ectopic nerve activity associated with 06.07.2007 US 958594 P neuropathic pain.", BRAIN RESEARCH 17 OCT 03.10.2007 US 997510 P 1997,vol. 771, no. 2, 17 October 1997 (1997-10-17), pages 228-237, XP002486707, ISSN: 0006-8993 (43) Date of publication of application: • STRICHARTZ G R: "The inhibition of sodium 02.05.2012 Bulletin 2012/18 currents in myelinated nerve by quaternary derivatives of lidocaine.", THE JOURNAL OF (62) Document number(s) of the earlier application(s) in GENERAL PHYSIOLOGY JUL 1973, vol.
    [Show full text]
  • Drugs to Avoid in Brugada Syndrome Patients January 2015
    Concerns: ______________________ Date of birth: ______________________ Dear colleague, Because of cardiologic and/or genetic evidence of Brugada syndrome in the patient mentioned above, I advised him/her not to take the following prescriptions: DRUGS TO BE AVOIDED Antiarrhythmic drugs*: Ajmaline, Allapinine, Ethacizine, Flecainide, Pilsicainide, Procainamide, Propafenone Psychotropic drugs: Amitriplyline, Clomipramine, Desipramine, Lithium, Loxapine, Nortriptyline, Oxcarbazepine, Trifluoperazine Anesthetics / analgesics*: Bupivacaine, Procaine, Propofol Other substances: Acetylcholine, Alcohol (toxicity), Cannabis, Cocaine, Ergonovine *For advice please visit www.brugadadrugs.org/emergencies DRUGS PREFERABLY AVOIDED Antiarrhythmic drugs: Amiodarone, Cibenzoline, Disopyramide, Lidocaine*, Propranolol, Verapamil, Vernakalant Psychotropic drugs: Bupropion, Carbamazepine, Clothiapine, Cyamemazine, Dosulepine, Doxepine, Fluoxetine, Fluvoxamine, Imipramine, Lamotrigine, Maprotiline, Paroxetine, Perphenazine, Phenytoin, Thioridazine Anesthetics / analgesics: Ketamine, Tramadol Other substances: Demenhydrinate, Diphenhydramine, Edrophonium, Indapamide, Metoclopramide, Terfenadine/Fexofenadine * Lidocaine use for local anesthesia (e.g. by dentists) does seem to be safe if the amount administrated is low and if it is combined with adrenaline (epinephrine) which results in a local effect only. Further, in case of fever, close (electrocardiographic) monitoring is appropriate in combination with lowering of the body temperature (e.g. by using Paracetamol/Acetaminophen).
    [Show full text]
  • Ethmozine and Ethacizine - New Antiarrhythmic Drugs with Defibrillating Properties
    ETHMOZINE AND ETHACIZINE - NEW ANTIARRHYTHMIC DRUGS WITH DEFIBRILLATING PROPERTIES Dalia Varon, Moshe Rechavi, Mordechai Erez, Gabriella Goldberg, Mordechai Manoach and Natalia V. Kaverina* Department of Physiology and Pharmacology, Tel Aviv University School of Medicine, Tel-Aviv, Israel *Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia ABSTRACT Ventricular fibrillation (VF) is a life-threatening arrhythmia that leads to death unless electrical defibrillation is applied in time. Recent publications indicate that VF can be either sustained (SVF), requiring electrical defibrillation, or transient (TVF), reverting spontaneously into sinus rhythm. Since VF cannot be totally prevented by drugs, a new antiarrhythmic therapeutic approach has been proposed: drug- induced enhancement of the ability of the heart to defibrillate by itself. In this study we examined the defibrillating potency of two antiarrhythmic phenothiazines, ethmozine (ETM) and ethacizine (ETA), as well as their effects on catecholamine uptake and on the electrophysiological properties of the myocardial cell membrane. The antiarrhythmic-defibrillatory activity was examined in cats; the inhibitory effect on [3H]-norepinephrine (NE) uptake was examined in rat brain synaptosomes, and the electrophysiological membrane effects were examined by microelectrode recordings in perfused strips of heart ventricle from guinea-pigs. The results indicate that: 1. ETA exhibits similar but stronger antiarrhythmic-defibrillating and NE reuptake inhibitory effects than ETM; 2. ETA at ΙΟ-6 Μ decreases ventricular conduction time and increases Vmax while ETM at this concentration does not change them; 3. The defibrillating ability of the drugs can be related to their inhibitory potency on NE reuptake. Accepted 8 August 1993 © FREUND PUBLISHING HOUSE LTD., 1993 299 Vol.
    [Show full text]
  • Sodium Channel Na Channels; Na+ Channels
    Sodium Channel Na channels; Na+ channels Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential. www.MedChemExpress.com 1 Sodium Channel Inhibitors, Agonists, Antagonists, Activators & Modulators (+)-Kavain (-)-Sparteine sulfate pentahydrate Cat. No.: HY-B1671 ((-)-Lupinidine sulfate pentahydrate) Cat. No.: HY-B1304 (+)-Kavain, a main kavalactone extracted from Piper (-)-Sparteine sulfate pentahydrate ((-)-Lupinidine methysticum, has anticonvulsive properties, sulfate pentahydrate) is a class 1a antiarrhythmic attenuating vascular smooth muscle contraction agent and a sodium channel blocker. It is an through interactions with voltage-dependent Na+ alkaloid, can chelate the bivalents calcium and and Ca2+ channels. magnesium. Purity: 99.98% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg Size: 10 mM × 1 mL, 50 mg (Rac)-AMG8379 20(S)-Ginsenoside Rg3 ((Rac)-AMG8380) Cat. No.: HY-108425B (20(S)-Propanaxadiol; S-ginsenoside Rg3) Cat.
    [Show full text]
  • Ep 2425858 A2
    (19) & (11) EP 2 425 858 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 07.03.2012 Bulletin 2012/10 A61K 45/06 (2006.01) A61K 31/167 (2006.01) A61K 31/085 (2006.01) A61K 31/165 (2006.01) (2006.01) (21) Application number: 11007950.6 A61P 29/00 (22) Date of filing: 19.11.2007 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Bean, Bruce P. HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE Waban, MA 02468 (US) SI SK TR • Woolf, Clifford J. Newton, MA 02458 (US) (30) Priority: 20.11.2006 US 860124 P 06.07.2007 US 958594 P (74) Representative: Lahrtz, Fritz 03.10.2007 US 997510 P Isenbruck Bösl Hörschler LLP Patentanwälte (62) Document number(s) of the earlier application(s) in Prinzregentenstraße 68 accordance with Art. 76 EPC: DE-81675 München (DE) 07862114.1 / 2 101 819 Remarks: (71) Applicants: This application was filed on 30-09-2011 as a • President and Fellows of Harvard College divisional application to the application mentioned Cambridge, MA 02138 (US) under INID code 62. • The General Hospital Corporation Boston, MA 02114 (US) (54) Compositions for treating pain and pruritus (57) The invention features a method for inhibiting through the channel-forming receptor when the receptor one or more voltage-gated ion channels in a cell by con- is activated. The invention also features a quarternary tacting the cell with (i) a first compound that activates a amine derivative or other permanently or transiently channel-forming receptor that is present on nociceptors charged derivative of a compound that inhibits one or and/or pruriceptors; and (ii) a second compound that in- more voltage-gated ion channels when applied to the in- hibits one or more voltage-gated ion channels when ap- ternal face of the channels but does not substantially in- plied to the internal face of the channels but does not hibit said channels when applied to the external face of substantially inhibit said channels when applied to the the channels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • Permanently Charged Sodium and Calcium Channel Blockers As Anti-Inflammatory Agents
    (19) TZZ ¥Z¥_T (11) EP 2 995 303 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.03.2016 Bulletin 2016/11 A61K 31/165 (2006.01) A61K 31/277 (2006.01) A61K 45/06 (2006.01) A61P 25/00 (2006.01) (2006.01) (2006.01) (21) Application number: 15002768.8 A61P 11/00 A61P 13/00 A61P 17/00 (2006.01) A61P 1/00 (2006.01) (2006.01) (2006.01) (22) Date of filing: 09.07.2010 A61P 27/02 A61P 29/00 A61P 37/08 (2006.01) (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • WOOLF, Clifford, J. GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Newton, MA 02458 (US) PL PT RO SE SI SK SM TR • BEAN, Bruce, P. Waban, MA 02468 (US) (30) Priority: 10.07.2009 US 224512 P (74) Representative: Lahrtz, Fritz (62) Document number(s) of the earlier application(s) in Isenbruck Bösl Hörschler LLP accordance with Art. 76 EPC: Patentanwälte 10797919.7 / 2 451 944 Prinzregentenstrasse 68 81675 München (DE) (71) Applicants: • President and Fellows of Harvard College Remarks: Cambridge, MA 02138 (US) This application was filed on 25-09-2015 as a • THE GENERAL HOSPITAL CORPORATION divisional application to the application mentioned Boston, MA 02114 (US) under INID code 62. • CHILDREN’S MEDICAL CENTER CORPORATION Boston, Massachusetts 02115 (US) (54) PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS (57) The present invention relates to a composition or a kit comprising N-methyl etidocaine for use in a method for treating neurogenic inflammation in a patient, wherein the kit further comprises instructions for use.
    [Show full text]
  • Clinical Aspects of Aconitum Preparations*
    Reviews 1017 Clinical Aspects of Aconitum Preparations* Authors Chi-Jung Tai1,3 #, Mohamed El-Shazly1, 2 #, Tung-Ying Wu4, Kun-Tai Lee5, 6, Dezső Csupor 7, Judit Hohmann7, Fang-Rong Chang1, 8,9, 10, Yang-Chang Wu1,4, 11,12 Affiliations The affiliations are listed at the end of the article Key words Abstract tion has changed with the application of new l" Aconitum ! technologies for the accurate analysis of its toxic l" Ranunculaceae Aconite species have played an important role in components and the development of efficient de- l" fuzi human history. Aconitum species have been used toxification protocols. Some Asian countries l" monkshood worldwide as poisons as well as remedies. Their started small clinical trials to evaluate the potency l" traditional Chinese medicine l" Ayurvedic medicine potential in targeting several ailments such as and safety of different marketed aconite prepara- pain, rheumatism, and lethargy has been recog- tions. The current review summarizes therapeu- nized by Western, Chinese, and Indian health care tic uses of aconite preparations in China, Taiwan, practitioners. Aconite use in herbal preparations India, and Japan. It also highlights clinical trial re- has declined, especially in Europe and the United sults with special emphasis on their limitations. States, in the first half of the twentieth century Modern drugs and pharmacopoeial preparations due to several reported toxicity cases. The situa- derived from aconite are also discussed. received March 16, 2015 revised May 14, 2015 accepted May 17, 2015 Introduction Rchb. [6]. Several isoquinoline alkaloids and phe- Bibliography ! nethylamine derivatives have also been isolated, DOI http://dx.doi.org/ Aconitum, also known as monkshood, wolfʼs bane, such as higenamine from A.
    [Show full text]
  • Clinical Aspects of Aconitum Preparations*
    Reviews 1017 Clinical Aspects of Aconitum Preparations* Authors Chi-Jung Tai1,3 #, Mohamed El-Shazly1, 2 #, Tung-Ying Wu4, Kun-Tai Lee5, 6, Dezső Csupor 7, Judit Hohmann7, Fang-Rong Chang1, 8,9, 10, Yang-Chang Wu1,4, 11,12 Affiliations The affiliations are listed at the end of the article Key words Abstract tion has changed with the application of new l" Aconitum ! technologies for the accurate analysis of its toxic l" Ranunculaceae Aconite species have played an important role in components and the development of efficient de- l" fuzi human history. Aconitum species have been used toxification protocols. Some Asian countries l" monkshood worldwide as poisons as well as remedies. Their started small clinical trials to evaluate the potency l" traditional Chinese medicine l" Ayurvedic medicine potential in targeting several ailments such as and safety of different marketed aconite prepara- pain, rheumatism, and lethargy has been recog- tions. The current review summarizes therapeu- nized by Western, Chinese, and Indian health care tic uses of aconite preparations in China, Taiwan, practitioners. Aconite use in herbal preparations India, and Japan. It also highlights clinical trial re- has declined, especially in Europe and the United sults with special emphasis on their limitations. States, in the first half of the twentieth century Modern drugs and pharmacopoeial preparations due to several reported toxicity cases. The situa- derived from aconite are also discussed. received March 16, 2015 revised May 14, 2015 accepted May 17, 2015 Introduction Rchb. [6]. Several isoquinoline alkaloids and phe- Bibliography ! nethylamine derivatives have also been isolated, DOI http://dx.doi.org/ Aconitum, also known as monkshood, wolfʼs bane, such as higenamine from A.
    [Show full text]
  • Wo 2008/063603 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 29 May 2008 (29.05.2008) PCT WO 2008/063603 A2 (51) International Patent Classification: WOOLF, Clifford, J. [US/US]; 107 Franklin Street, A61K 45/00 (2006.01) A61K 31/167 (2006.01) Newton, MA 02458 (US). A61K 31/085 (2006.01) A61P 29/00 (2006.01) A61K 31/165 (2006.01) (74) Agent: BELLIVEAU, Michael, J.; Clark & Elbing LLP, 101 Federal Street, Boston, MA 021 10 (US). (21) International Application Number: PCT/US2007/024174 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (22) International Filing Date: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 19 November 2007 (19.1 1.2007) ES, FT, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (25) Filing Language: English LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, (26) Publication Language: English PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW 60/860,124 20 November 2006 (20. 11.2006) US 60/958,594 6 July 2007 (06.07.2007) US (84) Designated States (unless otherwise indicated, for every 60/997,510 3 October 2007 (03.10.2007) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicants (for all designated States except US): PRES¬ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), IDENT AND FELLOWS OF HARVARD COLLEGE European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, [US/US]; 17 Quincy Street, Cambridge, MA 02138 FR, GB, GR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, PL, (US).
    [Show full text]
  • 2-Phenyl-1-(3-Pyrrolidin-1-Il-Propyl)-1 H-Indole Hydrochloride (SS-68): Antiarrhythmic and Cardioprotective Activity and Its Molecular Mechanisms of Action (Part I)
    Research Results in Pharmacology 4(2): 133–150 UDC: 615.22 DOI 10.3897/rrpharmacology.4.28592 Research Article 2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1 H-indole hydrochloride (SS-68): Antiarrhythmic and cardioprotective activity and its molecular mechanisms of action (Part I) Saida K. Bogus1, Pavel A. Galenko-Yaroshevsky1, Konstantin F. Suzdalev2, Galina V. Sukoyan3, Valery G. Abushkevich1 1 Kuban State Medical University, 4 Sedina Str., Krasnodar 350063, Russian Federation 2 Southern Federal University, 7 Zorge St., Rostov-on-Don 344090, Russian Federation 3 International Research Centre for Biophysics and of Introduction of New Biomedical Technologies, 19 Kayrskaya str., Tbilisi 0137 Georgia Corresponding author: Saida K. Bogus ([email protected]) Academic editor: Mikhail Pokrovskii ♦ Received 24 April 2018 ♦ Accepted 26 May 2018 ♦ Published 21 June 2018 Citation: Bogus SK, Galenko-Yaroshevsky PA, Suzdalev KF, Sukoyan GV, Abushkevich VG (2018) 2-phenyl-1-(3-pyrrolidin-1- il-propyl)-1 H-indole hydrochloride (SS-68): Antiarrhythmic and cardioprotective activity and its molecular mechanisms of action (Part I). Research Results in Pharmacology 4(2): 133–150. https://doi.org/10.3897/rrpharmacology.4.28592 Abstract Introduction. The problem of heart rhythm disturbances is one of the most urgent topics of modern cardiology. Ac- cording to the currently available concepts, 1,2- and 1,3-disubstituted aminoindole derivatives, which compound 2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1H-indole hydrochloride (SS-68) belongs to, are a promising chemical
    [Show full text]